RELATIVITY-104:纳武利尤单抗+瑞拉利单抗联合铂类双药化疗一线治疗IV期或复发NSCLC的II期研究
RELATIVITY-104 Part 2是首个头对头II期概念验证研究,评估纳武利尤单抗+瑞拉利单抗+铂类双药化疗(PDCT)对比纳武利尤单抗+PDCT一线治疗IV期/复发NSCLC。主要终点ORR未达到(51.3% vs 45.0%),PFS HR 0.89(90%CI 0.72-1.09)。在PD-L1≥1%且非鳞癌亚组中观察到获益趋势(ORR 58.0% vs 39.6%;PFS HR 0.68,90%CI 0.46-1.01;OS HR 0.60,90%CI 0.38-0.94)。
要点
- 全人群主要终点ORR未达到,PFS HR 0.89(90%CI 0.72-1.09)。
- PD-L1≥1%非鳞癌亚组ORR 58.0% vs 39.6%,PFS HR 0.68,OS HR 0.60。
- 安全性可控,与既往报告一致,支持在PD-L1≥1%非鳞癌人群进一步开展III期研究。
核心结论
- 在全随机人群中,标准治疗基础上加用瑞拉利单抗未改善结局。
- PD-L1≥1%且非鳞癌亚组观察到积极趋势,支持进一步研究。
研究设计与样本
- II期、概念验证、头对头研究RELATIVITY-104 Part 2,患者1:1随机分组。
- 比较纳武利尤单抗+瑞拉利单抗+PDCT与纳武利尤单抗+PDCT一线治疗IV期/复发NSCLC。
- 主要终点为BICR评估的ORR,次要终点包括BICR评估的PFS、DOR、亚组ORR和PFS及安全性。
主要发现
- 主要终点未达到:ORR 51.3%(纳武利尤单抗+瑞拉利单抗+PDCT)vs 45.0%(纳武利尤单抗+PDCT)。
- PFS HR 0.89(90%CI 0.72-1.09)。
- PD-L1≥1%非鳞癌亚组:ORR 58.0% vs 39.6%;PFS HR 0.68(90%CI 0.46-1.01);OS HR 0.60(90%CI 0.38-0.94)。
- 安全性可控,与既往报告一致。
关键数值与推荐
- 主要终点ORR:51.3% vs 45.0%,未达到。
- PFS HR 0.89(90%CI 0.72-1.09)。
- PD-L1≥1%非鳞癌亚组ORR 58.0% vs 39.6%,PFS HR 0.68(90%CI 0.46-1.01),OS HR 0.60(90%CI 0.38-0.94)。
临床怎么用
- 全人群一线标准治疗基础上加用瑞拉利单抗未显示获益。
- PD-L1≥1%非鳞癌患者可能从纳武利尤单抗+瑞拉利单抗+PDCT中获益,需III期RELATIVITY-1093进一步验证。
局限性
- II期概念验证研究,样本量有限。
- 亚组分析为探索性,需谨慎解读。
- 主要终点未达到,全人群结果不支持进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed death 1-blocking antibody, nivolumab, plus lymphocyte-activation gene 3-blocking antibody, relatlimab, is approved for advanced melanoma. We report results from Part 2 of RELATIVITY-104, the first phase II, proof-of-concept, head-to-head study to evaluate first-line nivolumab plus relatlimab plus platinum doublet chemotherapy (PDCT) versus nivolumab plus PDCT in patients with stage IV/recurrent non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: In Part 2, patients were randomized 1:1 to nivolumab plus relatlimab plus PDCT or nivolumab plus PDCT. The primary endpoint was objective response rate (ORR) per blinded independent central review (BICR). Secondary endpoints included progression-free survival (PFS) and duration of response (DOR) per BICR, ORR and PFS by subgroups, and safety. Exploratory analyses included overall survival (OS), biomarker, translational, and patient-reported outcomes. RESULTS: In part 2, the primary endpoint was not met (ORR, 51.3% for nivolumab plus relatlimab plus PDCT versus 45.0% for nivolumab plus PDCT); PFS hazard ratio (HR; 90% confidence interval [CI]) was 0.89 (0.72 to 1.09). A trend towards improved clinical benefit was seen with nivolumab plus relatlimab plus PDCT in a subgroup of patients with programmed death ligand 1 (PD-L1) ≥1% and nonsquamous histology (ORR: 58.0% versus 39.6%; PFS: HR, 0.68; 90% CI 0.46 to 1.01). A potential improvement in OS was observed with nivolumab plus relatlimab plus PDCT in the PD-L1 ≥1% nonsquamous subgroup (HR, 0.60; 90% CI 0.38 to 0.94). The safety profile of nivolumab plus relatlimab plus PDCT was manageable and consistent with previous reports. CONCLUSION: In RELATIVITY-104, the addition of relatlimab to standard-of-care did not improve outcomes in the unselected all-randomized population. However, positive trends observed in the subgroup of patients with tumor PD-L1 ≥1% and nonsquamous NSCLC supports further investigation in these patients in the phase III RELATIVITY-1093 study. CLINICALTRIALS: gov identifier: NCT04623775.
引用
- Girard N, Burotto M, Paz-Ares LG, et al. Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study. Ann Oncol. 2026. PMID: 42918419. doi:10.1016/j.annonc.2026.10.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。